

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

NCT07175493

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Keymed Biosciences Co.Ltd
Enrollment	158 participants

Key Eligibility Criteria

Inclusion (5)

- Voluntary provision of written informed consent and ability to comply with protocol requirements.
- Age ≥18 years, male or female.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
- Confirmed diagnosis of immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), mixed autoimmune hemolytic anemia (mAIHA) or Evans Syndrome.
- Relapsed or refractory autoimmune hemolytic anemia.

Exclusion (5)

- Secondary ITP or AIHA caused by any reason. Subjects with positive autoimmune antibodies but without a clear diagnosis of any other autoimmune diseases are allowed to be enrolled.
- Other types of AIHA or other types of cytopenia
- History of critical diseases that, in the opinion of the investigator, may pose a risk to the safety of subjects or whose exacerbation during the study could compromise the efficacy or safety analysis of the results.
- Received any treatment of anti-B Cell Maturation Antigen(BCMA) antibody.
- Evaluated unsuitable to participant in this study by investigator.

Locations (3 total)

Henan Cancer Hospital, Zhengzhou, Henan, China

Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China

Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China